If you have been reading about aliquoting and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Water is a central factor in peptide degradation because it enables hydrolysis and mobilizes reactive species. Lyophilized or dry powders typically remain stable for longer than solutions when kept cool and dry. Oxygen can drive oxidation, particularly for sulfur-containing residues, while light can catalyze side-chain damage. Buffer choice and pH influence charge state and can accelerate or slow deamidation and aggregation. Freeze-thaw cycles may concentrate solutes or promote ice-induced aggregation, so minimizing such cycles is a common handling goal.
Lyophilization removes water under vacuum from a frozen solution, leaving a porous cake or powder. Formulation excipients such as sugars or polyols can stabilize structure during freezing and drying and can raise the glass transition temperature. Residual moisture in the final product remains a critical variable because even small amounts can support hydrolysis over time. Storage recommendations often specify desiccation, darkness, and low temperature, though exact conditions depend on the peptide and its intended use. Stability studies measure changes under defined conditions rather than predicting absolute shelf life.
Peptides are short chains of amino acids linked by amide bonds. Their stability depends on sequence, length, and the chemical environment. Common degradation routes include hydrolysis of the peptide backbone, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and aggregation through hydrophobic or electrostatic interactions. These processes can alter mass, charge, or biological activity, so storage conditions aim to slow them. The relative importance of each route varies widely among peptides.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized or dry peptide material |
| Solubility class | Often freely soluble in water | Depends on sequence and counterion |
| Typical dry storage temperature | -20 °C or lower | Cooler conditions generally slow degradation |
| Common degradation route | Hydrolysis, oxidation, deamidation | Relative importance varies by sequence |
| Typical analytical method | RP-HPLC and LC-MS | Used to assess purity and mass |
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
Temperature is a primary factor because most degradation reactions proceed more slowly at lower temperatures. Lyophilized peptides are commonly held at -20 °C or below, although some sequences remain stable at 2–8 °C for limited periods. Moisture uptake during handling can accelerate hydrolysis, so sealed containers and desiccants are used. Solutions are generally less stable than powders and may require freezing at -80 °C or refrigeration, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation even when the storage temperature is otherwise suitable.
Light, oxygen, and pH influence peptide integrity through specific side-chain reactions. Methionine and cysteine residues are susceptible to oxidation, and tryptophan can degrade under strong light. Inert gas overlays and amber glass or opaque containers reduce these risks. pH affects charge, solubility, and the rate of deamidation or aggregation; a value that minimizes one pathway may increase another. The optimal pH and buffer for a given peptide are often determined experimentally, and open questions remain about predicting stability from sequence alone.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
== Autism == William Shaw became focused on autism in 1993, and has claimed that acetaminophen may be a major cause of autism. Nevertheless, as of 2017, there still was no good evidence to claim that acetaminophen caused autism. Shaw has also alleged without credible scientific evidence that yeast infections cause autism. He was accused of "exploit[ing] the parents' understandable and desperate search for a cause of their children's autism". Shaw has endorsed dangerous and discredited chelation treatments for autism.
== Sequence == The amino acid sequence (44 long) of human GHRH is: HO - Tyr - Ala - Asp - Ala - Ile - Phe - Thr - Asn - Ser - Tyr - Arg - Lys - Val - Leu - Gly - Gln - Leu - Ser - Ala - Arg - Lys - Leu - Leu - Gln - Asp - Ile - Met - Ser - Arg - Gln - Gln - Gly - Glu - Ser - Asn - Gln - Glu - Arg - Gly - Ala - Arg - Ala - Arg - Leu - NH2
Eflornithine, sold under the brand name Ornidyl among others, is a medication used to treat African trypanosomiasis (sleeping sickness) and excessive hair growth on the face in women. Specifically it is used for the second stage of sleeping sickness caused by T. b. gambiense and may be used with nifurtimox. It is taken intravenously (injection into a vein) or topically. It is an ornithine decarboxylase inhibitor. Common side effects when applied as a cream include rash, redness, and burning. Side effects of the injectable form include bone marrow suppression, vomiting, and seizures. It is unclear if it is safe to use during pregnancy or breastfeeding. It is recommended typically for children over the age of 12. Eflornithine was developed in the 1970s and came into medical use in 1990. It is on the World Health Organization's List of Essential Medicines. In the United States the injectable form can be obtained from the US Centers for Disease Control and Prevention. In regions of the world where sleeping sickness is common, eflornithine is provided for free by the World Health Organization.
Sources: en.wikipedia.org
Based on in vitro studies, it has been estimated that MAO-A is responsible for about 81% of psilocin's phase I hepatic metabolism. Psilocin and its metabolites are also glucuronidated by UDP-glucuronyltransferases (UGTs). UGT1A10 and UGT1A9 appear to be the most involved. Psilocybin's glucuronidated metabolites include psilocin-O-glucuronide and 4-HIAA-O-glucuronide. Approximately 80% of psilocin in blood plasma is in conjugated form, and conjugated psilocin levels are about fourfold higher than levels of free psilocin. Plasma 4-HIAA levels are also much higher than those of free psilocin. Norpsilocin (4-HO-NMT), formed from psilocin via demethylation mediated by the cytochrome P450 enzyme CYP2D6, is known to occur in mice in vivo and with human recombinant CYP2D6 in vitro but was not detected in humans in vivo. An oxidized psilocin metabolite of unknown chemical structure is also formed by hydroxyindole oxidase activity of CYP2D6. Oxidized psilocin is possibly a quinone-type structure like psilocin iminoquinone (4-hydroxy-5-oxo-N,N-DMT) or psilocin hydroquinone (4,5-dihydroxy-N,N-DMT). Additional metabolites formed by CYP2D6 may also be present. Besides CYP2D6, CYP3A4 showed minor activity in metabolizing psilocin, though the produced metabolite is unknown. Other cytochrome P450 enzymes besides CYP2D6 and CYP3A4 appear unlikely to be involved in psilocin metabolism.
=== Thermal stability === The melting point of sucrose esters is between 40 °C and 60 °C depending on the type of fatty acids and the degree of substitution. Sucrose esters can be heated to 185 °C without losing their functionality. However, the color of the product might change due to caramelization of sucrose.
. Chemical engineers once used the kilogram-mole (notation kg-mol), which is defined as the number of entities in 12 kg of 12C, and often referred to the mole as the gram-mole (notation g-mol), then defined as the number of entities in 12 g of 12C, when dealing with laboratory data. Late 20th-century chemical engineering practice came to use the kilomole (kmol), which was numerically identical to the kilogram-mole (until the 2019 revision of the SI, which redefined the mole by fixing the value of the Avogadro constant, making it very nearly equivalent to but no longer exactly equal to the gram-mole), but whose name and symbol adopt the SI convention for standard multiples of metric units – thus, kmol means 1000 mol. This is equivalent to the use of kg instead of g. The use of kmol is not only for "magnitude convenience" but also makes the equations used for modelling chemical engineering systems coherent. For example, the conversion of a flowrate of kg/s to kmol/s only requires dividing by the molar mass in kg/kmol (which is equivalent to g/mol, as
Sources: en.wikipedia.org
{\displaystyle k_{1}\cdot (PA)^{t}+k_{2}\cdot (PB)^{t}+k_{3}\cdot (PC)^{t}\geq 2^{t}{\sqrt {k_{1}k_{2}k_{3}}}\left({\frac {(PD)^{t}}{\sqrt {k_{1}}}}+{\frac {(PE)^{t}}{\sqrt {k_{2}}}}+{\frac {(PF)^{t}}{\sqrt {k_{3}}}}\right),}
In now discredited work, Fredrickson and Losada postulated in 2005 that the ratio of positive to negative affect, known as the critical positivity ratio, can distinguish individuals that flourish from those that do not. Languishing was characterized by a ratio of positive to negative affect of 2.5. Optimal functioning or flourishing was argued to occur at a ratio of 4.3. The point at which flourishing changes to languishing is called the Losada line and is placed at the positivity ratio of 2.9. Those with higher ratios were claimed to have broader behavioral repertoires, greater flexibility and resilience to adversity, more social resources, and more optimal functioning in many areas of their life. The model also predicted the existence of an upper limit to happiness, reached at a positivity ratio of 11.5. Fredrickson and Losada claimed that at this limit, flourishing begins to disintegrate and productivity and creativity decrease. They suggested as positivity increased, so to "appropriate negativity" needs to increase. This was described as time-limited, practicable feedback connected to specific circumstances, i.e. constructive criticism. This positivity ratio theory was widely accepted until 2013, when Nick Brown, a graduate student in applied positive psychology, co-authored a paper with Alan Sokal and Harris Friedman, showing that the mathematical basis of the paper was invalid. Fredrickson partially retracted the paper, agreeing that the math may be flawed, but maintaining that the empirical evidence is still valid.
== Inside the body == Hemolysis inside the body can be caused by a large number of medical conditions, including some parasites (e.g., Plasmodium), some autoimmune disorders (e.g., autoimmune haemolytic anaemia), drug-induced hemolytic anemia, atypical hemolytic uremic syndrome (aHUS)), some genetic disorders (e.g., Sickle-cell disease or G6PD deficiency), or blood with too low a solute concentration (hypotonic to cells). Hemolysis can lead to hemoglobinemia due to hemoglobin released into the blood plasma, which plays a significant role in the pathogenesis of sepsis and can lead to increased risk of infection due to its inhibitory effects on the innate immune system.
Sources: en.wikipedia.org
Peptide degradation can arise from hydrolysis, oxidation, deamidation, and aggregation. The dominant route depends on the peptide sequence and the storage environment. Temperature, moisture, oxygen, light, and pH all influence the rate.
Freezing slows many chemical reactions but does not stop all degradation. Repeated freeze-thaw cycles can promote aggregation or precipitation. Dry powders and solutions may respond differently to freezing.
pH affects the charge state of ionizable groups and can influence deamidation, hydrolysis, and aggregation. A pH that stabilizes one peptide may destabilize another. Buffer components can also participate in degradation or stabilization.
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.